Xeptiva Therapeutics
Pipeline / Exploratory · Dog · Obesity

Obesity in dogs

Xeptiva’s tech­nol­ogy applied to the immune-meta­bolic mech­a­nisms of canine obesity.

ProgramExploratory
SpeciesDog
IndicationObesity
StageTarget identification
The disease

Why it matters

Obesity is one of the most common nutri­tional dis­or­ders in vet­eri­nary medicine and affects between 30% and 60% of dogs world­wide, a figure that keeps rising in urban areas.

It short­ens life expectancy by 1.5 to 2 years and pro­motes chronic disease such as dia­betes, osteoarthri­tis, car­dio­vas­cu­lar and res­pi­ra­tory dis­or­ders, while reduc­ing mobil­ity, mood and vital­ity.

Target and mechanism

What the vaccine does

Obesity is a chronic inflam­ma­tory con­di­tion: adipose tissue sus­tains low-grade sys­temic inflam­ma­tion through the innate immune system and pro-inflam­ma­tory cytokines. Xeptiva’s tech­nol­ogy is designed to mod­u­late this inflam­ma­tion and support func­tional recov­ery in over­weight dogs, beyond weight man­age­ment through diet and exer­cise.

How the platform works →
Evidence

Preclinical studies

  • This program is cur­rently in pre­clin­i­cal studies.
Partnering

Interested in this program?

Pro­to­cols, study reports and the reg­u­la­tory package are avail­able to qual­i­fied part­ners under con­fi­den­tial­ity.

Request data room accessBack to the pipeline